Top Links

Articles Related to anticancer

Compliance in the Duration of Administration of Anticancer Chemotherapy: Comparative Study of Two Different Administration Modalities (PVC versus IVAD)

Objective: To evaluate the compliance of chemotherapy administration duration by comparing the peripheral venous catheter (PVC) route with the implantable venous access device (IVAD).Keywords: Chemotherapy; Gravity perfusion; Peripheral venous; Implantable venous access deviceIntroduction Methods: This was a retrospective study that analyzed 566 cycles of chemotherapy administered by PVC at the Cancer Unit of Yalgado Ou├ędraogo University Hospital and 258 cycles administered by IVAD at the Oncology Department of Treichville University Hospital in Abidjan. We compared the differences between the programmed duration of chemotherapy and the actual duration of administration according to the two routes of administration.
View complete article: PDF  |  Full-text

A New Bi-Functional Derivative of Polyethylene Glycol as Molecular Carrier for Eugenol and Ibuprofen

Eugenol (EU) and ibuprofene (IBU) were covalently bound to a bi-functionalized PEG, used as molecular carrier of drugs and the release kinetics of the two bioactive molecules was studied in vitro in buffer solution at pH 7.4, in simulated gastric fluid and in mouse plasma.
View complete article: PDF  |  Full-text

Development of Severe Hypophosphatemia from Acquired Fanconi Syndrome during Treatment with Abiraterone

The first patient was a 77 year old man who had been on abiraterone for 12 months before his phosphorous was checked. At that point, it was 0.6 mg/dl, which is severely decreased. A full work up for hypophosphatemia showed normal parathyroid hormone and 25-hydroxyvitamin D. A urine study showed inappropriate excretion of phosphorous along with aminoaciduria and normoglycemic glucosuria.
View complete article: PDF  |  Full-text

Liposphere: A Versatile Controlled Release Carrier for Hydrophobic Drugs

Researchers have been inventing new drugs since time immemorial. Of late it is established that the development of new drugs alone is not sufficient to ensure progress in drug therapy. The missing link is a potential strategy.It involves the apt selection of drug carrier systems.
View complete article: PDF  |  Full-text  | Digital
 
 

Perspectives and Potential Applications of Ruthenium-Based Nanocarriers for Cancer Therapy

Cancer is a highly heterogeneous disease characterised by continuous uncontrolled growth and expansion of abnormal cells. In general, in tumor cells the signalling pathways regulating cellular processes, as cell growth and division and cell to cellcommunication result strongly altered.
View complete article: PDF  |  Full-text  | Digital
 
 


Editorial Board Members Related to anticancer

YUNBO LI

Professor
Department of Pharmacology
Campbell University School of Osteopathic Medicine
United States

Donald Cairns

Professor
School of Pharmacy and Life Sciences
Robert Gordon University
United Kingdom

Daniela Iannazzo

University Researcher
Department of Electronic Engineering, Industrial Chemistry and Engineering
University of Messina
Italy

Peng Zhan

Associate professor
School of pharmaceutical sciences
Shandong University
China

Rula M. Darwish

Professor
Department of Pharmaceutical Microbiology
University of Jordan
Jordan

Jack Ho Wong

School of Biomedical Sciences
Chinese University of Hong Kong
Hong Kong

Mridula Chopra

Senior Lecturer
School of Pharmacy and Biomedical Sciences
University of Portsmouth
United Kingdom

Tao Liu

Children's Cancer Institute
University of New South Wales
Australia
Submit Manuscript